Clinical trial registration, sponsored by MycoMedica Life Sciences PBC, registered 14 Sep 2026.
Phase 1 · not yet recruiting · n = 32
Tags: Registry, Psilocybin.
New registrations include psilocybin for methamphetamine use disorder, borderline personality disorder, nicotine craving and premenstrual dysphoric disorder, and a National Institute on Aging trial pairing psilocybin with cognitive training. Results were posted for psilocybin in depression and anxiety in Parkinson's disease.
How much weight it carries: Registrations show what is being attempted, not what was found. (Registry, Plans, not results)
Newly registered first-in-indication safety study of psilocybin for premenstrual dysphoric disorder, run by MycoMedica
How much weight it carries: Trial registry movements: what is being attempted, not what was found. (Registry, Plans, not results)